INFORMATIONAL PURPOSES ONLY. Not medical, legal, or travel advice. Verify with official sources before acting. See corrections log.
Right to try laws and requirements in Maryland. Citations, verification dates, and source links for every data point.
| Dimension | Value | Citation | Source | Verified | Confidence |
|---|---|---|---|---|---|
| Have Enacted State Right to Try Laws | have state RTT laws sources differ | Md. Code, Health-Gen. §§ 21-2B-01 to 21-2B-06 (2017 Md. Laws Ch. 771, as amended by 2024 Md. Laws Ch. 960)“Altering certain provisions of law authorizing certain activity by manufacturers of investigational drugs, biological products, or devices under the Right to Try Act to apply to manufacturers of certain individualized investigational treatments”Note: Maryland enacted a classic Right to Try Act in 2017 (HB 584, Ch. 771). Ch. 960 of 2024 (HB 676) repealed and reenacted §§ 21-2B-01 to -06. It deleted the classic 'investigational drug, biological product, or device' (phase-one) definition and replaced it with 'individualized investigational treatment'. The current subtitle still sits under the Right to Try Act but covers only individualized treatments for life-threatening or severely debilitating illness. Under the strict definition (a classic phase-1 RTT statute in force) the answer would be FALSE today. Best value TRUE because a state RTT act was enacted and remains in force in modified form. | Link | 2026-10-09 | medium |
| Enacted Right to Try Laws Before Federal Law | 2017 | 2017 Md. Laws Ch. 771 (HB 584)“Approved by the Governor - Chapter 771” | Link | 2026-10-09 | high |
| Require Individualized Manufacturer Approval for RTT | require individualized approval | Md. Code, Health-Gen. § 21-2B-01(f); 2024 Md. Laws Ch. 960 (HB 676)““Individualized investigational treatment” means a drug, biological product, or device that is unique to and produced exclusively for use by an individual based on the genetic profile of the individual.”Note: Maryland enacted 'Right to Try Act - Individualized Investigational Treatments' (HB 676, approved by the Governor as Chapter 960, 2024). It covers individualized gene therapy, ASOs and neoantigen vaccines for life-threatening or severely debilitating illness. The stored FALSE is wrong, and the stored note's wording is also wrong. | Link | 2026-10-09 | high |
| Provide Manufacturer Liability Protection Under RTT | provide liability shield | Md. Code, Health-Gen. § 21-2B-05“This subtitle does not create a private cause of action against a manufacturer of an individualized investigational treatment or against another person involved in the care of an eligible patient”Note: 'No private cause of action' clause (not an immunity), conditioned on the manufacturer 'complying in good faith with this subtitle' and having 'exercised reasonable care'. Ch. 960 of 2024 shows the same clause existed for investigational drugs in the 2017 classic version. | Link | 2026-10-09 | high |
| Require Insurer Coverage of Investigational Treatments | do not require coverage | Md. Code, Health-Gen. § 21-2B-06“A carrier, third–party administrator, or government agency may provide coverage for the cost of an individualized investigational treatment” | Link | 2026-10-09 | high |
View full Maryland profile (all layers) · Report an error on this page